BORON-CONTAINING PROTEASOME INHIBITORS FOR USE AFTER PRIMARY CANCER THERAPY

摘要

The present disclosure relates to methods or dosing regimens comprising a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, for treating cancer, or preventing cancer recurrence or progression; wherein ring A, Z1 and Z2 are as defined herein.